The partnership with the American College of Lifestyle Medicine to expand AspyreRx access aligns with Better Therapeutics' mission and could lead to increased usage and prescriptions of AspyreRx. This strategic move not only has the potential to improve patient outcomes in underserved communities but also positions BTTX for growth by tapping into a large, previously underserved market. The initiative's focus on type 2 diabetes, a widespread and growing health issue, further underscores its potential impact on BTTX's market presence and financial performance.